Top

International Journal of Colorectal Disease

Published in:

01-07-2014 | Original Article

Neoadjuvant chemoradiation with concomitant boost radiotherapy associated to capecitabine in rectal cancer patients

Authors: Mattia F. Osti, Linda Agolli, Stefano Bracci, Luigi Masoni, Maurizio Valeriani, Teresa Falco, Vitaliana De Sanctis, Riccardo Maurizi Enrici

Published in: International Journal of Colorectal Disease | Issue 7/2014

Abstract

Purpose

The primary end-points were complete pathological response and local control. Secondary end-points were survivals, anal sphincter preservation, and toxicity profile.

Methods

Patients with T3/T4 and or N+ rectal cancer (n = 65) were treated with preoperative concomitant boost radiotherapy (55 Gy/25 fractions) associated to concurrent chemotherapy with oral capecitabine.

Results

All patients completed the programmed treatment. The complete pathological response was achieved by 17 % of the patients. Anal sphincter preservation surgery was possible for 86 % of the patients with low rectal cancer (≤5 cm from the anal verge). The T-stage and N-stage downstaging were achieved by 40 and 58 % of the patients, respectively. Circumferential radial margin was involved (close/positive) in eight patients. After a median follow-up of 26 months, local and distant recurrence occurred in two and 11 patients, respectively. The 3-year overall survival and disease-free survival were 86.8 and 81 %, respectively. Non-hematological ≥ grade 3 toxicities were observed in 15 % of the patients. On univariate analysis N-downstaging and positive circumferential radial margin were significantly associated with worse overall survival (p = 0.003 and p = 0.023, respectively), disease-free survival (p = 0.001 and p = 0.036, respectively), and metastasis-free survival (MFS) (p = 0.001 and p = 0.038, respectively).On multivariate analysis, the N-downstaging were significantly associated with better overall survival (OS) (p = 0.022).

Conclusions

Our data support the efficacy of preoperative treatment for rectal cancer in terms of local outcomes. Radiation treatment intensification may have a biological rationale; longer follow-up is needed.

Boyle P, Ferlay J (2005) Cancer incidence and mortality in Europe, 2004. Ann Oncol 16:481–488PubMedCrossRef

Anonymous (1997) Improved survival with preoperative radiotherapy in resectable rectal cancer. Swedish Rectal Cancer Trial. N Eng J Med 336:980–987

Folkesson J, Birgisson H, Pahlman L (2005) Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 23:5644–5650PubMedCrossRef

Heald RJ, Ryall RDH (1986) Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1:1479–1482PubMedCrossRef

Rullier E, Goffre B, Bonnel C, Zerbib F, Caudry M, Saric J (2001) Preoperative radiochemotherapy and sphincter-saving resection for T3 carcinomas of the lower third of the rectum. Ann Surg 234:633–640PubMedCentralPubMedCrossRef

García-Aguilar J, Hernandez de Anda E, Sirivongs P, Lee SH, Madoff RD, Rothenberger DA (2003) A pathologic complete response to preoperative chemoradiation is associated with lower local recurrence and improved survival in rectal cancer patients treated by mesorectal excision. Dis Colon Rectum 46:298–304PubMedCrossRef

Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625PubMedCrossRef

Meta-analysis in Group Cancer (1998) Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis in Group Cancer. J Clin Oncol 16:301–308

Glynne-Jones R, Harrison M (2007) Locally advanced rectal cancer: what is the evidence for induction chemoradiation? Oncologist 12:1309–1318PubMedCrossRef

10.

Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, Utoh M, Mori K, Weidekamm E, Reigner B (2000) Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients. Cancer Chemother Pharmacol 45:291–297PubMedCrossRef

11.

Kim JC, Kim TW, Kim JH, Yu CS, Kim HC, Chang HM, Ryu MH, Park JH, Ahn SD, Lee SW, Shin SS, Kim JS, Choi EK (2005) Preoperative concurrent radiotherapy with capecitabine before total mesorectal excision in LARC. Int J Radiat Oncol Biol Phys 63:346–353PubMedCrossRef

12.

de las Heras M, Arias F, del Moral-Avila R, Gómez-Millán J, Jiménez E, Wals A, Tisaire JL, Alcantara MP (2013) Multicentre phase II clinical trial of preoperative capecitabine with concurrent radiotherapy in patients with locally advanced rectal cancer. Clin Transl Oncol 15:294–299PubMedCrossRef

13.

Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P (2003) CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 13:176–181PubMedCrossRef

14.

Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Color Dis 12:19–23CrossRef

15.

Glimelius B, Oliviera J (2009) Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 20(suppl 4):54–56PubMed

16.

Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R, German Rectal Cancer Study Group (2004) Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740PubMedCrossRef

17.

Roh MS, Colangelo LH, O’Connell MJ, Yothers G, Deutsch M, Allegra CJ, Kahlenberg MS, Baez-Diaz L, Ursiny CS, Petrelli NJ, Wolmark N (2009) Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP R-03. J Clin Oncol 27:5124–5130PubMedCentralPubMedCrossRef

18.

Sebag-Montefiore D, Stephens RJ, Steele R, Monson J, Grieve R, Khanna S, Quirke P, Couture J, de Metz C, Myint AS, Bessell E, Griffiths G, Thompson LC, Parmar M (2009) Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373:811–820PubMedCentralPubMedCrossRef

19.

Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, Daban A, Bardet E, Beny A, Ollier JC, EORTC Radiotherapy Group Trial 22921 (2006) Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123PubMedCrossRef

20.

Gérard JP, Azria D, Gourgou-Bourgade S, Martel-Laffay I, Hennequin C, Etienne PL, Vendrely V, François E, de La Roche G, Bouché O, Mirabel X, Denis B, Mineur L, Berdah JF, Mahé MA, Bécouarn Y, Dupuis O, Lledo G, Montoto-Grillot C, Conroy T (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28:1638–1644PubMedCrossRef

21.

Caravatta L, Padula GD, Picardi V, Macchia G, Deodato F, Massaccesi M, Sofo L, Pacelli F, Rotondi F, Cecere G, Sallustio G, Di Lullo L, Piscopo A, Mignogna S, Bonomo P, Cellini N, Valentini V, Morganti AG (2011) Concomitant boost radiotherapy and multidrug chemotherapy in the neoadjuvant treatment of locally advanced rectal cancer: results of a phase II study. Acta Oncol 50:1151–1157PubMedCrossRef

22.

Vestermark LW, Jacobsen A, Qvortrup C, Hansen F, Bisgaard C, Baatrup G, Rasmussen P, Pfeiffer P (2008) Long-term results of a phase II trial of high-dose radiotherapy (60 Gy) and UFT/l-leucovorin in patients with non-resectable locally advanced rectal cancer (LARC). Acta Oncol 47:428–433PubMedCrossRef

23.

Vestermark LW, Jensen HA, Pfeiffer P (2012) High-dose radiotherapy (60 Gy) with oral UFT/folinic acid and escalating doses of oxaliplatin in patients with non-resectable locally advanced rectal cancer (LARC): a phase I trial. Acta Oncol 51:311–317PubMedCrossRef

24.

Engineer R, Mohandas KM, Shukla PJ, Shrikhande SV, Mahantshetty U, Chopra S, Goel M, Mehta S, Patil P, Ramadwar M, Deodhar K, Arya S, Shrivastava SK (2013) Escalated radiation dose alone vs. concurrent chemoradiation for locally advanced and unresectable rectal cancers: results from phase II randomized study. Int J Color Dis 28:959–966CrossRef

25.

Krishnan S, Janjan NA, Skibber JM, Rodriguez-Bigas MA, Wolff RA, Das P, Delclos ME, Chang GJ, Hoff PM, Eng C, Brown TD, Crane CH, Feig BW, Morris J, Vadhan-Raj S, Hamilton SR, Lin EH (2006) Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys 66:762–771PubMedCrossRef

26.

Kim DY, Kim TH, Jung KH, Chang HJ, Lim SB, Choi HS, Jeong SY, Nam TK, Ryu SY, Lee DS, Choi SI, Kang JH, Yoon SC (2006) Preoperative chemoradiotherapy with concomitant small field boost irradiation for locally advanced rectal cancer: a multi-institutional phase II study (KROG 04-01). Dis Colon Rectum 49:1684–1691PubMedCrossRef

27.

van Gijn W, Marijnen CA, Nagtegaal ID, Kranenbarg EM, Putter H, Wiggers T, Rutten HJ, Påhlman L, Glimelius B, van de Velde CJ, Dutch Colorectal Cancer Group (2011) Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12:575–582PubMedCrossRef

28.

McCarthy K, Pearson K, Fulton R, Hewitt J (2012) Pre-operative chemoradiation for non-metastatic locally advanced rectal cancer. Cochrane Database Syst Rev. doi:10.1002/14651858.CD008368.pub2

29.

Ceelen WP, Van Nieuwenhove Y, Fierens K (2009) Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev (1). doi:10.1002/14651858.CD006041.pub2

30.

Pach R, Kulig J, Richter P, Gach T, Szura M, Kawalska T (2012) Randomized clinical trial on preoperative radiotherapy 25Gy in rectal cancer—treatment results at 5-year follow up. Langenbeck’s Arch Surg 397:801–807CrossRef

31.

Koukourakis GV (2012) Role of radiation therapy in neoadjuvant era in patients with locally advanced rectal cancer. World J Gastrointest Oncol 4:230–237PubMedCentralPubMedCrossRef

32.

Bernstein TE, Endreseth BH, Romundstad P, Wibe A, Norwegian Colorectal Cancer Group (2009) Circumferential resection margin as a prognostic factor in rectal cancer. Br J Surg 96:1348–1357PubMedCrossRef

33.

Tilney HS, Rasheed S, Northover JM, Tekkis PP (2009) The influence of circumferential resection margins on long-term outcomes following rectal cancer surgery. Dis Colon Rectum 52:1723–1729PubMedCrossRef

34.

Gosens MJ, Klaassen RA, Tan-Go I, Rutten HJ, Martijn H, van den Brule AJ, Nieuwenhuijzen GA, van Krieken JH, Nagtegaal ID (2007) Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal carcinoma. Clin Cancer Res 13:6617–6623PubMedCrossRef

35.

Lee JH, Kim DY, Nam TK, Yoon SC, Lee DS, Park JW, Oh JH, Chang HJ, Yoon MS, Jeong JU, Jang HS (2012) Long-term follow-up of preoperative pelvic radiation therapy and concomitant boost irradiation in locally advanced rectal cancer patients: a multi-Institutional phase II study (KROG 04-01). Int J Radiat Oncol Biol Phys 84:955–961PubMedCrossRef

36.

Zorcolo L, Rosman AS, Restivo A, Pisano M, Nigri GR, Fancellu A, Melis M (2012) Complete pathological response after combined modality treatment for rectal cancer and long-term survival: a meta-analysis. Ann Surg Oncol 19:2822–2832PubMedCrossRef

37.

Codina Cazador A, Farres Coll R, Olivet Pujol F, Martin Grillo A, Pujadas de Palol M, Gómez Romeu N, Julia Bergkvist D, Ortiz Duran R, Diez Gómez E (2013) Clinical and oncological results of the pathological complete response in rectal cancer after neoadjuvant treatment. Cir Esp 91:417–423PubMedCrossRef

Title: Neoadjuvant chemoradiation with concomitant boost radiotherapy associated to capecitabine in rectal cancer patients
Authors: Mattia F. Osti
Linda Agolli
Stefano Bracci
Luigi Masoni
Maurizio Valeriani
Teresa Falco
Vitaliana De Sanctis
Riccardo Maurizi Enrici
Publication date: 01-07-2014
Publisher: Springer Berlin Heidelberg
Published in: International Journal of Colorectal Disease / Issue 7/2014
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-014-1879-x

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Neoadjuvant chemoradiation with concomitant boost radiotherapy associated to capecitabine in rectal cancer patients

Abstract

Purpose

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 7/2014

Rectal leiomyosarcoma in association with ulcerative colitis: a rare condition with an unusual presentation

Normalisation of colon transit time in a spina bifida adolescent after neurosurgery for retethering

Increased risk of stroke among patients with ulcerative colitis: a population-based matched cohort study

Microscopic colitis: clinical characteristics, treatment and outcomes in an Irish population

Erratum to: Adenocarcinoma on j-pouch after proctocolectomy for ulcerative colitis—case report and review of literature

Natural Orifice Transluminal Endoscopic Surgery (NOTES) for colon resections—analysis of the first 139 patients of the German NOTES Registry (GNR)